A Randomized Double-Blind Placebo Controlled Clinical Study for Comparative Evaluation of Efficacy and Tolerability of a Novel Composition and a Commercial Extract of Boswellia serrata in Improving Knee Joint Health of Non-Osteoarthritic Subjects.

aila Nutraceuticals0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

阶段: 未知
状态: 已完成
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

入选标准

•Ambulatory, male and female subjects 30 â?? 65 years of age with a Body Mass Index (BMI) of approximately 18 to 29.9 kg/m2.
•Only nonâ??osteoarthritic subjects with radio graphic evidence by Kellgren - Lawrence grade 0.
•Female subjects of childbearing potential must be using a medically acceptable form of birth control. Female subjects of non-childbearing potential must be amenorrheic for at least 1 year or had a hysterectomy and/or bilateral oophorectomy.
•Results of screening should be within normal range or considered not clinically significant by the Principal Investigator.
•Subjects having mild-to-moderate pain in knee joint upon completion of 30 sec Chair Stand Test or 80 meter Fast-Paced Walk Test, and otherwise no knee pain at rest.
•Be willing to refrain from taking ibuprofen, aspirin or other NSAIDS (other than paracetamol as rescue medication) or any other pain reliever (OTC or prescription) during the entire trial.
•Willing to sign the informed consent and comply with study procedure.

排除标准

•Subjects with any possible signs/ indications/ history of arthritis, joint disorders including dislocations and quadriceps tendons tear.
•History of underlying inflammatory arthropathy or severe RA or OA.
•Subjects having used any immunosuppressive drugs in the last 6 months (including steroids or biologics) and those with history of immune system and autoimmune disorders.
•Subjects with a history of knee or hip joint replacement surgery, or any hip or back pain which interferes with ambulation.
•Expectation of surgery during the study duration period.
•Female subjects, who are pregnant, breast feeding or planning to become pregnant.
•Subject having known allergy to non-steroidal anti-inflammatory drugs (NSAIDs) (including aspirin) or has a suspected hypersensitivity, allergy or sensitivity to herbal products.
•Subjects who have any physical disability which could interfere with their ability to perform the functional performance measures included in this protocol.
•History of Gout.
•Have taken any corticosteroid, indomethacin, glucosamine+ chondroitin, within 3 months prior to the Treatment Period, Visit 1 or intra-articular treatment / injections with corticosteroid or hyaluronic acid within 6 months preceding the treatment period.
•History of congestive heart failure or any vascular conditions.
•Subjects with HIV Positive status.
•Evidence or history of clinically significant (in the judgment of the Investigator) hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic or neurologic diseases, or malignancies, hypothyroidism.
•History of Systemic Lupus Erythematous (SLE).
•High alcohol intake ( >2 standard drinks per day) or use of recreational drugs (such as cocaine, methamphetamine, marijuana, etc.).
•History of psychiatric disorder that may impair the ability of subjects to provide written informed consent.
•Participation in any other trials involving investigational or marketed products within 30 days prior to the Screening Visit.
•Have taken acetaminophen / paracetamol, ibuprofen, aspirin or other NSAIDS or any other pain reliever (OTC or prescription) or any natural health product, (excluding vitamins), within 7 days prior to the Screening Visit.

研究者

发起方

aila Nutraceuticals

相似试验

已完成

2 期

A clinical study to assess efficacy and safety of Zanacid Duo in patient suffering from dyspepsia.

CTRI/2017/06/008781Emami Limited

已完成

不适用

A Clinical Trial Study to Evaluate the Safety & Efficacy of Herbal Extract on Bone Health in Healthy Adult Volunteers.

CTRI/2016/06/006978ITC Limited120

已完成

不适用

A Clinical Study to Evaluate Efficacy and Tolerability of an Herbal Medicine in Patients with Mild to Moderate Knee Osteoarthritis

CTRI/2019/10/021691aila Nutraceuticals90

招募中

3 期

A study in subjects with Symptomatic genetic heart disease comparing sponsors drug Mavacamten with dummy drug.

CTRI/2023/10/058870MyoKardia, Inc.

进行中（未招募）

2 期

A clinical trial to study the effect of ayurvedic drug TNF34 tablets in patients with clinical and subclinical hypothyroidism

CTRI/2022/10/046836Apex Laboratories Private Limited Research and Development Centre